The biopharma industry told the US Food and Drug Administration what guidance is needed to advance the use of artificial intelligence and machine learning in drug development, from having regulatory clarity on AI/ML’s use in assessing efficacy to transparency considerations and the scope of FDA’s oversight.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?